Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag tg-therapeutics

Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia

Delveinsight

FEBRUARY 9, 2021

Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. TG Therapeutics Wins FDA Nod for Ukoniq for Marginal Zone Lymphoma and Follicular Lymphoma. TG Therapeutics has announced the U.S.

FDA Approval

FDA Approval Marketing Research Protein

TG Therapeutics challenges Roche with FDA filing for CLL drug

pharmaphorum

DECEMBER 2, 2020

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. TG said it expects the data submission to be complete in the first half of 2021. The post TG Therapeutics challenges Roche with FDA filing for CLL drug appeared first on.

Drugs

Drugs Trials Antibody Marketing

Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia

TG Therapeutics challenges Roche with FDA filing for CLL drug

Stay Connected